Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.280
-0.490-2.48%
Volume:646.00K
Turnover:12.58M
Market Cap:16.81B
PE:4.73
High:19.770
Open:19.770
Low:19.270
Close:19.770
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:1.09
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.075
ROE:1.46%
ROA:-1.24%
PB:1.70
PE(LYR):4.73
PS:3.91

Loading ...

HUTCHMED (China) Ltd. files Form 3 initial beneficial ownership statement for CEO and CSO Su Wei-guo

Reuters
·
Mar 16

HUTCHMED (00013) completes vesting of 19,913 LTIP shares to CEO Dr Weiguo Su

Bulletin Express
·
Mar 16

CICC Maintains Outperform Rating on HUTCHMED with HK$30 Target Price

Stock News
·
Mar 12

HUTCHMED (China) Ltd. Files Initial Beneficial Ownership Statement for Director and CFO Cheng Chig Fung

Reuters
·
Mar 11

HUTCHMED (00013.HK) Vests 0.73 Million LTIP Shares to CEO and CFO

Bulletin Express
·
Mar 11

HUTCHMED Faces Dual Setbacks: New Drug Withdrawn, Core Products Decline

Deep News
·
Mar 11

HUTCHMED (China) Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 11

When Annual Report Meets Drug Withdrawal: Can HUTCHMED (00013) Break Its 20 Billion Valuation Stalemate?

Stock News
·
Mar 10

Hua Yuan Securities Reiterates "Buy" on HUTCHMED (00013), Sees Promise in ATTC Pipeline

Stock News
·
Mar 10

BRIEF-Hutchmed (China) Says Ipsen Initiates Market Withdrawal And Recall Of Tazverik In China

Reuters
·
Mar 10

HUTCHMED Commences Tazverik® Withdrawal and Product Recall

Stock News
·
Mar 09

HUTCHMED (China) Ltd - ІPsen Has Informed HUTCHMED That It Is Voluntarily Withdrawing TazverІK in US

THOMSON REUTERS
·
Mar 09

HUTCHMED (China) Ltd - Ipsen Initiates Market Withdrawal and Recall of Tazverik in China

THOMSON REUTERS
·
Mar 09

HUTCHMED initiates TAZVERIK recall in China, Hong Kong and Macau

Reuters
·
Mar 09

HUTCHMED (China): Withdrawal Not Expected to Impact Financial Guidance

THOMSON REUTERS
·
Mar 09

HUTCHMED (China) Ltd - Withdraws Tazverik in Chinese Mainland, Hong Kong, Macau; Ends All Active Clinical Trials

THOMSON REUTERS
·
Mar 09

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

GlobeNewswire
·
Mar 09

CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating

Stock News
·
Mar 09

BofA Securities Adjusts HUTCHMED Price Target to $21 From $22, Maintains Buy Rating

MT Newswires Live
·
Mar 06

HUTCHMED Announces Executive Reshuffle: Dr. Yansi Ya to Assume Senior and Lead Independent Director Role

Stock News
·
Mar 06